PUBLISHER: IMARC | PRODUCT CODE: 1540852
PUBLISHER: IMARC | PRODUCT CODE: 1540852
The global oxidative stress assay market size reached US$ 865.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,824.2 Million by 2032, exhibiting a growth rate (CAGR) of 8.4% during 2024-2032.
Oxidative stress is a health condition wherein excessive production of oxygen-derived free radicals within a cell or organism overwhelms the intrinsic antioxidant defenses. It causes oxidative damage to proteins, lipids and nucleic acids, which can further lead to the development of cancer, asthma, ischemia, diabetes, and cardiovascular and neurodegenerative diseases. It is assessed using a number of assays that help healthcare researchers gain a better understanding of the mechanisms and responses of the condition.
Free radicals can be produced due to biological factors, unhealthy dietary habits and air pollution. This, in confluence with the rising number of individuals who smoke and consume alcohol, is escalating the risk of developing oxidative stress, which, in turn, is strengthening the market growth. Apart from this, the development of various pathologic conditions and acceleration of the aging process on account of oxidative stress is also bolstering the market growth. Furthermore, the growing biopharmaceutical industry, increasing investments in the research and development (R&D) activities and technological advancements, such as high-content screening for drug discovery, are acting as other major factors stimulating the market growth. Moreover, oxidative stress is also being considered as a major factor contributing to the severity of the coronavirus disease (COVID-19). It is also being evaluated as a probable cause of multi-organ failure among patients. The ongoing studies on the interrelation between the disease and oxidative stress are expected to positively influence the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global oxidative stress assay market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, technology, test type and end user.
Reagents and Consumables
Instruments
Services
ELISA (Enzyme-Linked Immunosorbent Assay)
Flow Cytometry
Chromatography
Microscopy
High-Content Screening
Label-Free Detection
Others
Indirect Assays
Protein-Based Assays
Lipid-Based Assays
Nucleic Acid-Based Assays
Antioxidant Capacity Assays
Glutathione Assays
Ascorbic Acid Assays
Cell-Based Exogenous Antioxidant Assays
Enzyme-Based Assays
Reactive Oxygen Species-Based Assays
Pharmaceutical Industry
Research Institutes
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Abcam PLC, AMS Biotechnology (Europe) Ltd., Biovision Inc. (Boai NKY Medical Holdings Ltd.), Cell Biolabs Inc., Enzo Biochem Inc., ImmunoChemistry Technologies LLC, Merck KGaA, Oxford Biomedical Research, Promega Corporation, Qiagen N.V. and Thermo Fisher Scientific Inc.